Topics:
Breast Cancer • Medical Oncology • Triple negative • Journal Club ft. NEJM publications • Breast Cancer, Metastatic
Are there known biomarkers predictive of response or resistance to sacituzumab govitecan which should be incorporated into treatment decisions for metastatic TNBC?
Are there differences in outcome among the BRCA mutated subgroup, or others?
Answer from: Medical Oncologist at Academic Institution
In the ASCENT trial, we evaluate the association between Trop-2 expression and clinical outcomes. Overall, the median progression-free survival (PFS) was 6.9, 5.6, and 2.7 months for high, medium, and low Trop-2 scores, respectively with SG compared with 2.5, 2.2, and 1.6 months with standard chemot...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Sacituzumab govitecan is a relatively new drug, so the pattern of resistance is not completely understood. Recently, Dr. @Aditya Bardia and Dr. Ellisen shared data that they have identified two alterations thought to be linked to sacituzumab resistance. They did this by looking at pre-saci...